Novo Nordisk

Novo Nordisk ( (NVO) ) just unveiled an announcement. On 4 February 2026, Novo Nordisk A/S launched a share repurchase programme under EU Safe Harbour rules as...

Goldman Sachs analyst James Quigley downgraded Novo Nordisk (NVO) to Neutral from Buy with a price target of $41, down from $63. The firm cut estimates for Cagr...

Prothena ( (PRTA) ) has shared an announcement. On February 27, 2026, Prothena announced that its board had authorized a share repurchase plan allowing the com...

Novo Nordisk (NVO) announced that the US Food and Drug Administration has approved three new indications for once-weekly Sogroya injection 5 mg, 10 mg, or 15 mg...

Eli Lilly (NYSE:LLY) reported that its oral GLP-1 candidate orforglipron outperformed Novo Nordisk’s oral semaglutide in a head to head Phase 3 trial in adults...

Key Points Hims stock has been under pressure this year. The company turned in solid Q4 results, but issued soft Q1 guidance. The stock has fallen to an attr...

Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising. Hims & Hers (HIMS 1.39%) is in the middle of a ver...

Key Points Novo Nordisk lost another head-to-head trial against Eli Lilly. The company is cutting prices on weight-loss drugs in 2026. The stock looks cheap,...

If you are wondering whether Novo Nordisk’s recent share price slump has created a potential opportunity or a value trap, you are in the right place. The stock...

Novo Nordisk (NYSE:NVO), which develops and markets diabetes and obesity treatments, closed Wednesday at $38.16, down 1.11%. The stock slipped as investors weig...